OBJECTIVE: Programmed death-ligand 1 (PD-L1) expression in colorectal cancer (CRC) was implicated in predicting anti-PD-1/PD-L1 therapy efficacy. However, therapeutic response has also been found in patients without PD-L1 expression in the primary tumor. In the present study, we aimed to clarify the prevalence of PD-L1 in primary and metastatic CRC.
INTRODUCTION
Colorectal cancer (CRC) is one of the leading cancers worldwide, [1] [2] [3] and its incidence has increased by 22% from 2000 to 2013 in the United States 4 . In China, the prevention and treatment of CRC remain to be highly challenging tasks, 5 given the complicated risk factors such as genetic background, 6 environment, 7 microbiota 8 and immune-related disorders 9, 10 . In metastatic CRC, the outcomes related to surgery or adjuvant therapy remain poor. 11, 12 In comparison to conventional therapies, cancer immunotherapies generally show improved tolerability and long-lasting effects. [13] [14] [15] Among these, the novel checkpoint blockade therapies targeting programmed cell death 1 (PD-1) and its ligand, programmed death ligand-1 (PD-L1; also known as B7-H1 or CD274), have achieved unprecedented clinical effects in a wide range of tumors. [16] [17] [18] Multiple anti-PD-1 (nivolumab, pembrolizumab) and anti-PD-L1 monoclonal antibodies (MPDL3280A, Medi4736) are under evaluation for treating digestive cancers. In microsatellite instability-high (MSI-H) metastatic CRC, the checkpoint inhibition therapy has displayed promising effects; 19 therefore, it has been approved by the Food and Drug Administration (FDA) for the Critical Path Initiative (CPI) use in these patients, even though, a subset of MSI-H and most microsatellite stable CRCs will not respond to checkpoint inhibitor alone. 20 Therefore, selection criteria that could enable the identification of patients who may benefit from these agents are necessary. 21 Accumulating data are in favor of an association between PD-L1 expression in tumors and response to treatment. 22, 23 A study based on immunohistochemical (IHC) detection of PD-1, PD-L1 and PD-L2 expressions in melanoma, lung cancer, kidney cancer and CRC suggested that PD-L1 expression by tumor cells might be most closely correlated with a response to anti-PD-1 blockade. 24 Moreover, recent studies suggested a low rate of PD-L1 expression in CRC. In a study including 181 CRC subjects, PD-L1 expression was only detected in 16 (9%) cases. 25 Another study involving 454 CRC subjects reported PD-L1 expression in only 12% of the patients, and molecular characterizations suggested that PD-L1 positivity was associated with tumors arising through the serrated neoplasia pathway. 26 PD-L1 expression seems to correlate with patient's clinical outcome, but objective responses have been observed in PD-L1-negative tumors. 27 In addition, the expression of PD-L1 could be different in primary tumors as compared to metastatic tumors. Thus, sampling error may lead to misclassification of PD-L1 expression status, and may partially explain the reason why some patients without detected PD-L1 expression in the primary tumors have responded to PD-1 or PD-L1 inhibitors. 28 Since the therapies using immune checkpoint inhibitors are more likely to be used to treat metastatic CRC than resectable CRC, 29 the expression of PD-L1 in metastatic CRC may be a key factor for patient selection. However, whether PD-L1 expression in metastatic CRC may be represented by its presence in primary CRC remains unknown. Thus, here we aimed to determine the expression of PD-L1 in matched primary and metastatic CRC tissues in order to assess the extent of agreement between both conditions.
MATERIALS AND METHODS

Tissue samples
Tissue microarray containing CRC tissue samples was purchased from BioChip (Shanghai, China), with informed consent obtained from each patient. The tissue microarray included matched normal epithelium as well as primary and metastatic CRC tissue samples from 22 patients (more than one metastatic tumor in some of the patients). The study has been approved by the Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University (Shanghai, China).
IHC analysis
IHC analysis was performed as previously described. 2 Briefly, the tissue microarray slides were deparaffinized in xylene and rehydrated using a graded series of ethanol. Heat-induced antigen retrieval was carried out in high-pH antigen retrieval buffer (Dako Cytomation, Glostrup, Denmark). Endogenous peroxidase was blocked by incubation in 3% H 2 O 2 for 5 min. After blocking with goat serum in 5% bovine serum albumin (BSA), anti-PD-L1 (Abcam, Cambridge, MA, USA) was incubated with the tissue slides overnight at 4 C. Following incubation with secondary antibody, these sections were visualized by the horseradish peroxidase (HRP)-labelled polymer method. Immunostained sections were counterstained with hematoxylin, dehydrated in ethanol and cleared in xylene. Cases with complete clinicopathological data were successfully detected for PD-L1 expression by IHC (inclusion criteria: without loss of tissue during the process; both tumor cells and para-tumor sites could be observed). The staining intensity of PD-L1 in tumor cells was assigned with scores 0 (negative), 1 (weak), 2 (moderate) and 3 (strong). The membranous distribution pattern of PD-L1 and the expression of PD-L1 in inflammatory cells were evaluated as weak or strong.
Statistical analysis
Statistical analyses were performed using SPSS version 19 (IBM, Armonk, NY, USA). Comparisons between the groups were performed using two-sided Student's t-test (for sex and tumor volume), or Chi-square test (for histological type and other factors). A two-sided P value of less than 0.05 was considered statistically significant.
RESULTS
Patient demographics
The normal epithelium, primary and metastatic CRC tissue samples from 22 patients with a mean age of 59.3 years (range 46-73 years) were respectively analyzed for the expression of PD-L1 by IHC analysis. These included 13 cases of colon cancer and nine of rectal cancer, with 18 being adenocarcinomas, three papillary carcinomas and one mucoid carcinoma (Supplementary Table S1 ). The metastatic sites included liver (n = 15), lung (n = 2), abdominal wall (n = 3), mesentery (n = 1) and ureter (n = 1). In normal epithelial tissues, the expression of PD-L1 was weak and without obvious heterogeneity ( Supplementary Fig. S1 ).
Intratumoral heterogeneity of PD-L1 expression in metastatic and primary CRC Since the intratumoral heterogeneity of PD-L1 expression has been reported in other metastatic tumors such as breast cancer 30 and clear cell carcinoma, 31 we questioned whether metastatic CRC may also exhibit such a feature. To this end, we detected the expression of PD-L1 by IHC in both primary and metastatic CRC tissues. Interestingly, the heterogeneity of PD-L1 expressions was found in both primary (33.3% [3/9] ) and metastatic CRCs (22.2% [4/18] ), without significant difference in the rates (P = 0.65, Fig. 1 ).
Expression of PD-L1 in primary CRC was not representative of expression in metastatic CRC
The disagreement of PD-L1 expression between primary and metastatic tumors has been reported in lung cancer, 28 thus we aimed to clarify whether the expression of PD-L1 was consistent in primary and metastatic CRC. The expression of PD-L1 was evaluated as negative (score 0), weak (1), moderate (2) and strong (3) according to the predominant expression pattern found in the tissue section. Interestingly, a considerable fraction of metastatic lesions displayed higher expression levels of PD-L1 than the matched primary tumors (Fig. 2) . Such increased expression of PD-L1 was not limited in certain types of metastasis, but could be found in tumors that spread to liver, lung and other sites. Of note, consistent PD-L1 expression in primary and metastatic lesions could also be found in a subset of CRCs, with representative images shown in Figure 3 .
Prevalent upregulation of PD-L1 expression in metastatic CRC
By comparing the primary and metastatic lesions of the same patients, we found that PD-L1 expression was further increased in 12 of 22 metastatic tumors (Fig. 4a) . In contrast, only one metastatic tumor was found with decreased PD-L1 expression than in primary tumor (from weak to negative). The majority of increased PD-L1 expressions were changes from negative (n = 5) or weak (n = 4) to moderate expression (Fig. 4b) .
When PD-L1 expression was stratified according to IHC scores (0-1 as low; 2-3 as high), high expression of PD-L1 was found in 18 (81.8%) of 22 metastatic CRCs, being more prevalent than in primary CRCs (40.9% [9/22] ). The difference was found with statistical significance (P = 0.012, Fisher's exact test). More than two-thirds (9/13) of PD-L1-low primary tumors matched with PD-L1-high metastatic tumors (Fig. 4c) . In addition, half (9/18) of the PD-L1-high metastatic tumors linked to primary tumors with low PD-L1 expression (Fig. 4c) . Further focused analysis on liver metastasis revealed the same trend as found in all metastatic tumors (Supplementary Fig. S1 ). Therefore, it is highly challenging to estimate the expression of PD-L1 in metastatic CRC based on the condition in primary CRC, and vice versa.
DISCUSSION
The expression of PD-L1 in CRC may be associated with the response to immunotherapy, and our study showed that PD-L1 expression in primary CRC might not represent the condition in primary CRC. We also demonstrated that PD-L1 expression was considerably more prevalent in metastatic CRC than in primary CRC, thus providing potential explanation to the therapeutic responses found in patients with PD-L1-low primary CRCs.
Our analysis on matched primary and metastatic CRCs revealed that two-thirds of PD-L1-low primary tumors might match to PD-L1-high metastatic tumors. Thus, judging the positivity of PD-L1 expression merely based on primary tumor may cause an underestimation on the presence of PD-L1 in metastatic tumors. Meanwhile, it would be equally challenging to estimate the expression of PD-L1 in primary CRC based on the condition in metastatic tumors, because half of the PD-L1-high metastatic CRC may link to PD-L1-low primary tumors.
Currently, it is poorly understood how the expression of PD-L1 may be altered during the metastatis, but several regulatory mechanisms may be considered. On the genomic level, it is worthy to clarify if the copy number of PD-L1 (CD274) gene may change in the metastatic lesion, since genomic alterations are believed to be involved in CRC metastasis. 3, 32 Factors that may affect the transactivation of PD-L1 should also be tested, given the epigenetic alterations known to occur in metastatic CRC. 33 Moreover, post-translational modifications such as glycosylation, phosphorylation and ubiquitylation have also been reported to regulate the expression of PD-L1. 34 It is of importance to identify the driving factors that may affect the expression of PD-L1 during the metastatic process. Detection of such key regulatory factors in primary CRC may also help to predict the expression of PD-L1 in metastatic tumors. These efforts may provide useful information for the selection of patients for immunotherapy, and facilitate the development of novel routes for targeting PD-L1 in tumors.
In this study, the main limitation was the number of cases in each group. This was mainly due to the challenges in obtaining matched normal, primary and metastatic tumor samples. In future studies, it will be of interest to examine the alteration of PD-L1 expression in a larger set of tissue samples. It is also important to analyze the association between PD-L1 expression in metastatic CRC and the responses to immunotherapies.
In conclusion, our study showed that PD-L1 expression was more prevalent in metastatic CRC than in primary lesions, which may explain the therapeutic responses found in patients not expressing PD-L1 in the primary tumor. This finding warrants further investigation on the regulation of PD-L1 during 
